Breast Trials

A list of our early phase breast cancer trials which are open to recruitment at University College London Hospitals

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked IRAS Number, which will take you to the UCLH Find a Study database.

ELEVATE A Phase 1b/2, Open-label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)
IRAS Number:	1007543
Principal Investigator	Dr Rebecca Roylance
Drug Class/ Treatment:	Elacestrant (Estrogen Receptor Antangonist) + Various Combination
Patient Population:	ER+, HER2– Breast Cancer
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

ELECTRA (ELA-0121) A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic
IRAS Number:	1005373
Principal Investigator	Dr Elisavet Papadimitraki
Drug Class/ Treatment:	Elacestrant (Oral selective ER degrader)
Patient Population:	Women and men with brain metastasis from estrogen receptor positive, her-2 negative breast cancer
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

PAveMent Phase 1b study of Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
IRAS Number:	245336
Principal Investigator:	Dr Rebecca Roylance
Drug Class/ Treatment:	Palbociclib (CDK4 and CDK6 Inhibitor) + Avelumab (PD-L1 Monoclonal Antibody)
Patient Population:	AR+ Triple Negative Breast Cancer
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)